17 research outputs found
Efficacy of micronized progesterone-containing transdermal gel in the treatment of fibrocystic mastopathy: Results of a Russian study
Objective. To evaluate the effect of progestogel as monotherapy on quality of life and magnitude of pain syndrome in fibrocystic mastopathy (FMP). Subjects and methods. The time course of changes in its symptoms was estimated using the pain visual analogue scale (VAS), the SF-6 health survey questionnaire, and ultrasonography in 798 patients diagnosed with FMP. Results. The pain VAS scores were 5.7 (5.0; 7.0) at baseline and statistically significantly lower [(2.4 (1.0; 4.0)] and [1.0 (0.0; 2.0)] after 3 and 6 months, respectively (p<0.05). The rate of diffuse and nodular changes was decreased by 44.3 and 60.4%, respectively. That of cystic masses β₯10 mm or less was reduced by 61.8 and 4.3%, respectively. There were physical and emotional improvements. Conclusion. Three-month progestogel monotherapy for FMP contributes to a decline in the number and extent of cystic changes, significantly reduces the magnitude of pain syndrome, and improves the quality of physical and mental health. Β© Bionika Media Ltd
Efficacy of micronized progesterone-containing transdermal gel in the treatment of fibrocystic mastopathy: Results of a Russian study
Objective. To evaluate the effect of progestogel as monotherapy on quality of life and magnitude of pain syndrome in fibrocystic mastopathy (FMP). Subjects and methods. The time course of changes in its symptoms was estimated using the pain visual analogue scale (VAS), the SF-6 health survey questionnaire, and ultrasonography in 798 patients diagnosed with FMP. Results. The pain VAS scores were 5.7 (5.0; 7.0) at baseline and statistically significantly lower [(2.4 (1.0; 4.0)] and [1.0 (0.0; 2.0)] after 3 and 6 months, respectively (p<0.05). The rate of diffuse and nodular changes was decreased by 44.3 and 60.4%, respectively. That of cystic masses β₯10 mm or less was reduced by 61.8 and 4.3%, respectively. There were physical and emotional improvements. Conclusion. Three-month progestogel monotherapy for FMP contributes to a decline in the number and extent of cystic changes, significantly reduces the magnitude of pain syndrome, and improves the quality of physical and mental health. Β© Bionika Media Ltd
ΠΠΈΠ°Π³Π½ΠΎΡΡΠΈΠΊΠ° ΠΈ Π»Π΅ΡΠ΅Π½ΠΈΠ΅ ΡΠ°ΠΊΠ° ΠΌΠΎΠ»ΠΎΡΠ½ΠΎΠΉ ΠΆΠ΅Π»Π΅Π·Ρ: ΡΡΠΎ ΠΈΠ·ΠΌΠ΅Π½ΠΈΠ»ΠΎΡΡ Π·Π° 20 Π»Π΅Ρ
Objective of the Review: To describe the progressive development of new imaging techniques for diagnosing breast disorders and methods of conservative surgery for these conditions. Key Points: As the latest trends show, digital imaging techniques allowing for breast visualization have become most popular and improved detection of breast cancer at early stages. New diagnostic options opened up further possibilities for conservative surgery. Combined-modality treatment, including surgery, precise radiation therapy, and targeted pharmacotherapy, has accounted for better survival rates and a 12.5% reduction in mortality over the last 10 years. The implementation of new complex technologies requires substantial changes in the system of specialist training, harmonization of regulatory documents and identification of new approaches to universal screening. Modern techniques used at specialist cancer facilities to diagnose and treat breast cancer have been shown to improve the 5-year survival rate in patients with stage 1-2 breast cancer up to 96%. Conclusion: The current system for diagnosis and treatment of breast disorders is rather well developed. However, some extra efforts are required to achieve goals identified for health care givers, including further improvement of screening models and prevention strategies for breast diseases as well as actions to increase the awareness of malignancies among primary-care physicians and to inform women about risk factors for breast disorders and current screening and prevention programs. Timely treatment for benign breast disease is the earliest and most effective preventive care for malignancies.Π¦Π΅Π»Ρ ΠΎΠ±Π·ΠΎΡΠ°: ΠΏΠΎΠΊΠ°Π·Π°ΡΡ ΠΏΠΎΡΡΡΠΏΠ°ΡΠ΅Π»ΡΠ½ΠΎΠ΅ ΡΠ°Π·Π²ΠΈΡΠΈΠ΅ Π½ΠΎΠ²ΡΡ
ΡΠ΅Ρ
Π½ΠΎΠ»ΠΎΠ³ΠΈΠΉ Π»ΡΡΠ΅Π²ΠΎΠΉ Π΄ΠΈΠ°Π³Π½ΠΎΡΡΠΈΠΊΠΈ ΠΈ ΠΌΠ΅ΡΠΎΠ΄ΠΎΠ² ΠΎΡΠ³Π°Π½ΠΎΡΠ±Π΅ΡΠ΅Π³Π°ΡΡΠ΅Π³ΠΎ Π»Π΅ΡΠ΅Π½ΠΈΡ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΠΉ ΠΌΠΎΠ»ΠΎΡΠ½ΠΎΠΉ ΠΆΠ΅Π»Π΅Π·Ρ. ΠΡΠ½ΠΎΠ²Π½ΡΠ΅ ΠΏΠΎΠ»ΠΎΠΆΠ΅Π½ΠΈΡ. Π‘ΠΎΠ³Π»Π°ΡΠ½ΠΎ ΡΠ΅Π½Π΄Π΅Π½ΡΠΈΡΠΌ ΠΏΠΎΡΠ»Π΅Π΄Π½ΠΈΡ
Π»Π΅Ρ, Π½Π°ΠΈΠ±ΠΎΠ»ΡΡΠ΅Π΅ ΡΠ°Π·Π²ΠΈΡΠΈΠ΅ ΠΏΠΎΠ»ΡΡΠΈΠ»ΠΈ ΡΠΈΡΡΠΎΠ²ΡΠ΅ ΡΠ΅Ρ
Π½ΠΎΠ»ΠΎΠ³ΠΈΠΈ Π²ΠΈΠ·ΡΠ°Π»ΠΈΠ·Π°ΡΠΈΠΈ ΠΌΠΎΠ»ΠΎΡΠ½ΠΎΠΉ ΠΆΠ΅Π»Π΅Π·Ρ, ΡΡΠΎ ΠΏΠΎΠ²ΡΡΠΈΠ»ΠΎ Π²ΡΡΠ²Π»ΡΠ΅ΠΌΠΎΡΡΡ ΡΠ°Π½Π½ΠΈΡ
ΡΠΎΡΠΌ ΡΠ°ΠΊΠ° ΠΌΠΎΠ»ΠΎΡΠ½ΠΎΠΉ ΠΆΠ΅Π»Π΅Π·Ρ. ΠΠΎΠ²ΡΠ΅ Π²ΠΎΠ·ΠΌΠΎΠΆΠ½ΠΎΡΡΠΈ Π΄ΠΈΠ°Π³Π½ΠΎΡΡΠΈΠΊΠΈ ΠΎΡΠΊΡΡΠ»ΠΈ ΠΏΠ΅ΡΡΠΏΠ΅ΠΊΡΠΈΠ²Ρ ΠΎΡΠ³Π°Π½ΠΎΡΠΎΡ
ΡΠ°Π½ΡΡΡΠ΅Π³ΠΎ Π»Π΅ΡΠ΅Π½ΠΈΡ. ΠΠΎΠΌΠΏΠ»Π΅ΠΊΡΠ½ΠΎΠ΅ ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π½ΠΈΠ΅ Ρ
ΠΈΡΡΡΠ³ΠΈΡΠ΅ΡΠΊΠΈΡ
Π²ΠΌΠ΅ΡΠ°ΡΠ΅Π»ΡΡΡΠ², ΠΏΡΠ΅ΡΠΈΠ·ΠΈΠΎΠ½Π½ΠΎΠΉ Π»ΡΡΠ΅Π²ΠΎΠΉ ΠΈ ΡΠ°ΡΠ³Π΅ΡΠ½ΠΎΠΉ Π»Π΅ΠΊΠ°ΡΡΡΠ²Π΅Π½Π½ΠΎΠΉ ΡΠ΅ΡΠ°ΠΏΠΈΠΈ ΡΠ²Π΅Π»ΠΈΡΠΈΠ»ΠΎ ΠΏΡΠΎΠ΄ΠΎΠ»ΠΆΠΈΡΠ΅Π»ΡΠ½ΠΎΡΡΡ ΠΆΠΈΠ·Π½ΠΈ ΠΈ ΡΠ½ΠΈΠ·ΠΈΠ»ΠΎ ΡΠΌΠ΅ΡΡΠ½ΠΎΡΡΡ Π·Π° ΠΏΠΎΡΠ»Π΅Π΄Π½ΠΈΠ΅ 10 Π»Π΅Ρ Π½Π° 12,5%. ΠΠ½Π΅Π΄ΡΠ΅Π½ΠΈΠ΅ Π½ΠΎΠ²ΡΡ
ΡΠ»ΠΎΠΆΠ½ΡΡ
ΡΠ΅Ρ
Π½ΠΎΠ»ΠΎΠ³ΠΈΠΉ ΡΡΠ΅Π±ΡΠ΅Ρ ΠΏΠ΅ΡΠ΅ΡΡΡΠΎΠΉΠΊΠΈ ΡΠΈΡΡΠ΅ΠΌΡ ΠΏΠΎΠ΄Π³ΠΎΡΠΎΠ²ΠΊΠΈ ΠΊΠ°Π΄ΡΠΎΠ², ΠΎΠΏΡΠΈΠΌΠΈΠ·Π°ΡΠΈΠΈ Π½ΠΎΡΠΌΠ°ΡΠΈΠ²Π½ΡΡ
Π΄ΠΎΠΊΡΠΌΠ΅Π½ΡΠΎΠ² ΠΈ ΡΠ°Π·ΡΠ°Π±ΠΎΡΠΊΠΈ Π½ΠΎΠ²ΡΡ
ΠΏΠΎΠ΄Ρ
ΠΎΠ΄ΠΎΠ² ΠΊ ΠΎΡΠ³Π°Π½ΠΈΠ·Π°ΡΠΈΠΈ ΠΌΠ°ΡΡΠΎΠ²ΡΡ
ΠΏΡΠΎΠ²Π΅ΡΠΎΡΠ½ΡΡ
ΠΎΠ±ΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠΉ Π½Π°ΡΠ΅Π»Π΅Π½ΠΈΡ. Π‘ΠΎΠ²ΡΠ΅ΠΌΠ΅Π½Π½ΡΠ΅ ΡΠ΅Ρ
Π½ΠΎΠ»ΠΎΠ³ΠΈΠΈ Π΄ΠΈΠ°Π³Π½ΠΎΡΡΠΈΠΊΠΈ ΠΈ Π»Π΅ΡΠ΅Π½ΠΈΡ ΡΠ°ΠΊΠ° ΠΌΠΎΠ»ΠΎΡΠ½ΠΎΠΉ ΠΆΠ΅Π»Π΅Π·Ρ, ΡΠ΅Π°Π»ΠΈΠ·ΡΠ΅ΠΌΡΠ΅ Π² ΡΡΠ»ΠΎΠ²ΠΈΡΡ
ΡΠΏΠ΅ΡΠΈΠ°Π»ΠΈΠ·ΠΈΡΠΎΠ²Π°Π½Π½ΡΡ
ΠΎΠ½ΠΊΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΡ
ΡΡΡΠ΅ΠΆΠ΄Π΅Π½ΠΈΠΉ, ΠΏΠΎΠΊΠ°Π·ΡΠ²Π°ΡΡ ΠΏΠΎΠ·ΠΈΡΠΈΠ²Π½ΡΠ΅ ΡΠ΅Π½Π΄Π΅Π½ΡΠΈΠΈ Π² ΠΏΠΎΠ²ΡΡΠ΅Π½ΠΈΠΈ 5-Π»Π΅ΡΠ½Π΅ΠΉ Π²ΡΠΆΠΈΠ²Π°Π΅ΠΌΠΎΡΡΠΈ Π±ΠΎΠ»ΡΠ½ΡΡ
Ρ 1-2-ΠΉ ΡΡΠ°Π΄ΠΈΠ΅ΠΉ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΡ Π΄ΠΎ 96%. ΠΠ°ΠΊΠ»ΡΡΠ΅Π½ΠΈΠ΅. Π‘Π΅ΠΉΡΠ°Ρ Π΄ΠΎΡΡΠ°ΡΠΎΡΠ½ΠΎ Ρ
ΠΎΡΠΎΡΠΎ ΡΠ°Π·ΡΠ°Π±ΠΎΡΠ°Π½Π° ΡΠΈΡΡΠ΅ΠΌΠ° Π΄ΠΈΠ°Π³Π½ΠΎΡΡΠΈΠΊΠΈ ΠΈ Π»Π΅ΡΠ΅Π½ΠΈΡ ΠΏΠ°ΡΠΎΠ»ΠΎΠ³ΠΈΠΉ ΠΌΠΎΠ»ΠΎΡΠ½ΠΎΠΉ ΠΆΠ΅Π»Π΅Π·Ρ. ΠΠ΄Π½Π°ΠΊΠΎ Π΄Π»Ρ Π΄ΠΎΡΡΠΈΠΆΠ΅Π½ΠΈΡ ΠΏΠΎΡΡΠ°Π²Π»Π΅Π½Π½ΡΡ
ΠΏΠ΅ΡΠ΅Π΄ Π·Π΄ΡΠ°Π²ΠΎΠΎΡ
ΡΠ°Π½Π΅Π½ΠΈΠ΅ΠΌ Π·Π°Π΄Π°Ρ Π½ΡΠΆΠ½Ρ Π΄ΠΎΠΏΠΎΠ»Π½ΠΈΡΠ΅Π»ΡΠ½ΡΠ΅ ΡΡΠΈΠ»ΠΈΡ ΠΏΠΎ ΡΠΎΠ²Π΅ΡΡΠ΅Π½ΡΡΠ²ΠΎΠ²Π°Π½ΠΈΡ ΠΌΠΎΠ΄Π΅Π»Π΅ΠΉ ΡΠΊΡΠΈΠ½ΠΈΠ½Π³Π° ΠΈ ΠΌΠ΅ΡΠΎΠ΄ΠΎΠ² ΠΈΡ
ΠΏΡΠΎΡΠΈΠ»Π°ΠΊΡΠΈΠΊΠΈ, ΠΏΠΎΠ²ΡΡΠ΅Π½ΠΈΡ ΠΎΠ½ΠΊΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΎΠΉ Π½Π°ΡΡΠΎΡΠΎΠΆΠ΅Π½Π½ΠΎΡΡΠΈ Π²ΡΠ°ΡΠ΅ΠΉ ΠΏΠ΅ΡΠ²ΠΈΡΠ½ΠΎΠ³ΠΎ Π·Π²Π΅Π½Π° Π·Π΄ΡΠ°Π²ΠΎΠΎΡ
ΡΠ°Π½Π΅Π½ΠΈΡ, ΠΈΠ½ΡΠΎΡΠΌΠΈΡΠΎΠ²Π°Π½Π½ΠΎΡΡΠΈ ΠΆΠ΅Π½ΡΠΊΠΎΠ³ΠΎ Π½Π°ΡΠ΅Π»Π΅Π½ΠΈΡ ΠΎ ΡΠ°ΠΊΡΠΎΡΠ°Ρ
ΡΠΈΡΠΊΠ° ΡΠ°Π·Π²ΠΈΡΠΈΡ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΠΉ ΠΌΠΎΠ»ΠΎΡΠ½ΠΎΠΉ ΠΆΠ΅Π»Π΅Π·Ρ, Π΄Π΅ΠΉΡΡΠ²ΡΡΡΠΈΡ
ΠΏΡΠΎΠ³ΡΠ°ΠΌΠΌΠ°Ρ
ΡΠΊΡΠΈΠ½ΠΈΠ½Π³Π° ΠΈ ΠΏΡΠΎΡΠΈΠ»Π°ΠΊΡΠΈΠΊΠΈ. Π‘Π²ΠΎΠ΅Π²ΡΠ΅ΠΌΠ΅Π½Π½ΠΎ Π½Π°ΡΠ°ΡΠΎΠ΅ Π»Π΅ΡΠ΅Π½ΠΈΠ΅ Π΄ΠΎΠ±ΡΠΎΠΊΠ°ΡΠ΅ΡΡΠ²Π΅Π½Π½ΡΡ
Π΄ΠΈΡΠΏΠ»Π°Π·ΠΈΠΉ ΠΌΠΎΠ»ΠΎΡΠ½ΠΎΠΉ ΠΆΠ΅Π»Π΅Π·Ρ ΡΠ²Π»ΡΠ΅ΡΡΡ Π½Π°ΠΈΠ±ΠΎΠ»Π΅Π΅ ΡΠ°Π½Π½Π΅ΠΉ ΠΈ ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΠΉ ΠΏΡΠΎΡΠΈΠ»Π°ΠΊΡΠΈΠΊΠΎΠΉ ΠΎΠ½ΠΊΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΡ
Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΠΉ
ΠΠΈΠ°Π³Π½ΠΎΡΡΠΈΠΊΠ° ΠΈ Π»Π΅ΡΠ΅Π½ΠΈΠ΅ ΡΠ°ΠΊΠ° ΠΌΠΎΠ»ΠΎΡΠ½ΠΎΠΉ ΠΆΠ΅Π»Π΅Π·Ρ: ΡΡΠΎ ΠΈΠ·ΠΌΠ΅Π½ΠΈΠ»ΠΎΡΡ Π·Π° 20 Π»Π΅Ρ
Objective of the Review: To describe the progressive development of new imaging techniques for diagnosing breast disorders and methods of conservative surgery for these conditions. Key Points: As the latest trends show, digital imaging techniques allowing for breast visualization have become most popular and improved detection of breast cancer at early stages. New diagnostic options opened up further possibilities for conservative surgery. Combined-modality treatment, including surgery, precise radiation therapy, and targeted pharmacotherapy, has accounted for better survival rates and a 12.5% reduction in mortality over the last 10 years. The implementation of new complex technologies requires substantial changes in the system of specialist training, harmonization of regulatory documents and identification of new approaches to universal screening. Modern techniques used at specialist cancer facilities to diagnose and treat breast cancer have been shown to improve the 5-year survival rate in patients with stage 1-2 breast cancer up to 96%. Conclusion: The current system for diagnosis and treatment of breast disorders is rather well developed. However, some extra efforts are required to achieve goals identified for health care givers, including further improvement of screening models and prevention strategies for breast diseases as well as actions to increase the awareness of malignancies among primary-care physicians and to inform women about risk factors for breast disorders and current screening and prevention programs. Timely treatment for benign breast disease is the earliest and most effective preventive care for malignancies.Π¦Π΅Π»Ρ ΠΎΠ±Π·ΠΎΡΠ°: ΠΏΠΎΠΊΠ°Π·Π°ΡΡ ΠΏΠΎΡΡΡΠΏΠ°ΡΠ΅Π»ΡΠ½ΠΎΠ΅ ΡΠ°Π·Π²ΠΈΡΠΈΠ΅ Π½ΠΎΠ²ΡΡ
ΡΠ΅Ρ
Π½ΠΎΠ»ΠΎΠ³ΠΈΠΉ Π»ΡΡΠ΅Π²ΠΎΠΉ Π΄ΠΈΠ°Π³Π½ΠΎΡΡΠΈΠΊΠΈ ΠΈ ΠΌΠ΅ΡΠΎΠ΄ΠΎΠ² ΠΎΡΠ³Π°Π½ΠΎΡΠ±Π΅ΡΠ΅Π³Π°ΡΡΠ΅Π³ΠΎ Π»Π΅ΡΠ΅Π½ΠΈΡ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΠΉ ΠΌΠΎΠ»ΠΎΡΠ½ΠΎΠΉ ΠΆΠ΅Π»Π΅Π·Ρ. ΠΡΠ½ΠΎΠ²Π½ΡΠ΅ ΠΏΠΎΠ»ΠΎΠΆΠ΅Π½ΠΈΡ. Π‘ΠΎΠ³Π»Π°ΡΠ½ΠΎ ΡΠ΅Π½Π΄Π΅Π½ΡΠΈΡΠΌ ΠΏΠΎΡΠ»Π΅Π΄Π½ΠΈΡ
Π»Π΅Ρ, Π½Π°ΠΈΠ±ΠΎΠ»ΡΡΠ΅Π΅ ΡΠ°Π·Π²ΠΈΡΠΈΠ΅ ΠΏΠΎΠ»ΡΡΠΈΠ»ΠΈ ΡΠΈΡΡΠΎΠ²ΡΠ΅ ΡΠ΅Ρ
Π½ΠΎΠ»ΠΎΠ³ΠΈΠΈ Π²ΠΈΠ·ΡΠ°Π»ΠΈΠ·Π°ΡΠΈΠΈ ΠΌΠΎΠ»ΠΎΡΠ½ΠΎΠΉ ΠΆΠ΅Π»Π΅Π·Ρ, ΡΡΠΎ ΠΏΠΎΠ²ΡΡΠΈΠ»ΠΎ Π²ΡΡΠ²Π»ΡΠ΅ΠΌΠΎΡΡΡ ΡΠ°Π½Π½ΠΈΡ
ΡΠΎΡΠΌ ΡΠ°ΠΊΠ° ΠΌΠΎΠ»ΠΎΡΠ½ΠΎΠΉ ΠΆΠ΅Π»Π΅Π·Ρ. ΠΠΎΠ²ΡΠ΅ Π²ΠΎΠ·ΠΌΠΎΠΆΠ½ΠΎΡΡΠΈ Π΄ΠΈΠ°Π³Π½ΠΎΡΡΠΈΠΊΠΈ ΠΎΡΠΊΡΡΠ»ΠΈ ΠΏΠ΅ΡΡΠΏΠ΅ΠΊΡΠΈΠ²Ρ ΠΎΡΠ³Π°Π½ΠΎΡΠΎΡ
ΡΠ°Π½ΡΡΡΠ΅Π³ΠΎ Π»Π΅ΡΠ΅Π½ΠΈΡ. ΠΠΎΠΌΠΏΠ»Π΅ΠΊΡΠ½ΠΎΠ΅ ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π½ΠΈΠ΅ Ρ
ΠΈΡΡΡΠ³ΠΈΡΠ΅ΡΠΊΠΈΡ
Π²ΠΌΠ΅ΡΠ°ΡΠ΅Π»ΡΡΡΠ², ΠΏΡΠ΅ΡΠΈΠ·ΠΈΠΎΠ½Π½ΠΎΠΉ Π»ΡΡΠ΅Π²ΠΎΠΉ ΠΈ ΡΠ°ΡΠ³Π΅ΡΠ½ΠΎΠΉ Π»Π΅ΠΊΠ°ΡΡΡΠ²Π΅Π½Π½ΠΎΠΉ ΡΠ΅ΡΠ°ΠΏΠΈΠΈ ΡΠ²Π΅Π»ΠΈΡΠΈΠ»ΠΎ ΠΏΡΠΎΠ΄ΠΎΠ»ΠΆΠΈΡΠ΅Π»ΡΠ½ΠΎΡΡΡ ΠΆΠΈΠ·Π½ΠΈ ΠΈ ΡΠ½ΠΈΠ·ΠΈΠ»ΠΎ ΡΠΌΠ΅ΡΡΠ½ΠΎΡΡΡ Π·Π° ΠΏΠΎΡΠ»Π΅Π΄Π½ΠΈΠ΅ 10 Π»Π΅Ρ Π½Π° 12,5%. ΠΠ½Π΅Π΄ΡΠ΅Π½ΠΈΠ΅ Π½ΠΎΠ²ΡΡ
ΡΠ»ΠΎΠΆΠ½ΡΡ
ΡΠ΅Ρ
Π½ΠΎΠ»ΠΎΠ³ΠΈΠΉ ΡΡΠ΅Π±ΡΠ΅Ρ ΠΏΠ΅ΡΠ΅ΡΡΡΠΎΠΉΠΊΠΈ ΡΠΈΡΡΠ΅ΠΌΡ ΠΏΠΎΠ΄Π³ΠΎΡΠΎΠ²ΠΊΠΈ ΠΊΠ°Π΄ΡΠΎΠ², ΠΎΠΏΡΠΈΠΌΠΈΠ·Π°ΡΠΈΠΈ Π½ΠΎΡΠΌΠ°ΡΠΈΠ²Π½ΡΡ
Π΄ΠΎΠΊΡΠΌΠ΅Π½ΡΠΎΠ² ΠΈ ΡΠ°Π·ΡΠ°Π±ΠΎΡΠΊΠΈ Π½ΠΎΠ²ΡΡ
ΠΏΠΎΠ΄Ρ
ΠΎΠ΄ΠΎΠ² ΠΊ ΠΎΡΠ³Π°Π½ΠΈΠ·Π°ΡΠΈΠΈ ΠΌΠ°ΡΡΠΎΠ²ΡΡ
ΠΏΡΠΎΠ²Π΅ΡΠΎΡΠ½ΡΡ
ΠΎΠ±ΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠΉ Π½Π°ΡΠ΅Π»Π΅Π½ΠΈΡ. Π‘ΠΎΠ²ΡΠ΅ΠΌΠ΅Π½Π½ΡΠ΅ ΡΠ΅Ρ
Π½ΠΎΠ»ΠΎΠ³ΠΈΠΈ Π΄ΠΈΠ°Π³Π½ΠΎΡΡΠΈΠΊΠΈ ΠΈ Π»Π΅ΡΠ΅Π½ΠΈΡ ΡΠ°ΠΊΠ° ΠΌΠΎΠ»ΠΎΡΠ½ΠΎΠΉ ΠΆΠ΅Π»Π΅Π·Ρ, ΡΠ΅Π°Π»ΠΈΠ·ΡΠ΅ΠΌΡΠ΅ Π² ΡΡΠ»ΠΎΠ²ΠΈΡΡ
ΡΠΏΠ΅ΡΠΈΠ°Π»ΠΈΠ·ΠΈΡΠΎΠ²Π°Π½Π½ΡΡ
ΠΎΠ½ΠΊΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΡ
ΡΡΡΠ΅ΠΆΠ΄Π΅Π½ΠΈΠΉ, ΠΏΠΎΠΊΠ°Π·ΡΠ²Π°ΡΡ ΠΏΠΎΠ·ΠΈΡΠΈΠ²Π½ΡΠ΅ ΡΠ΅Π½Π΄Π΅Π½ΡΠΈΠΈ Π² ΠΏΠΎΠ²ΡΡΠ΅Π½ΠΈΠΈ 5-Π»Π΅ΡΠ½Π΅ΠΉ Π²ΡΠΆΠΈΠ²Π°Π΅ΠΌΠΎΡΡΠΈ Π±ΠΎΠ»ΡΠ½ΡΡ
Ρ 1-2-ΠΉ ΡΡΠ°Π΄ΠΈΠ΅ΠΉ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΡ Π΄ΠΎ 96%. ΠΠ°ΠΊΠ»ΡΡΠ΅Π½ΠΈΠ΅. Π‘Π΅ΠΉΡΠ°Ρ Π΄ΠΎΡΡΠ°ΡΠΎΡΠ½ΠΎ Ρ
ΠΎΡΠΎΡΠΎ ΡΠ°Π·ΡΠ°Π±ΠΎΡΠ°Π½Π° ΡΠΈΡΡΠ΅ΠΌΠ° Π΄ΠΈΠ°Π³Π½ΠΎΡΡΠΈΠΊΠΈ ΠΈ Π»Π΅ΡΠ΅Π½ΠΈΡ ΠΏΠ°ΡΠΎΠ»ΠΎΠ³ΠΈΠΉ ΠΌΠΎΠ»ΠΎΡΠ½ΠΎΠΉ ΠΆΠ΅Π»Π΅Π·Ρ. ΠΠ΄Π½Π°ΠΊΠΎ Π΄Π»Ρ Π΄ΠΎΡΡΠΈΠΆΠ΅Π½ΠΈΡ ΠΏΠΎΡΡΠ°Π²Π»Π΅Π½Π½ΡΡ
ΠΏΠ΅ΡΠ΅Π΄ Π·Π΄ΡΠ°Π²ΠΎΠΎΡ
ΡΠ°Π½Π΅Π½ΠΈΠ΅ΠΌ Π·Π°Π΄Π°Ρ Π½ΡΠΆΠ½Ρ Π΄ΠΎΠΏΠΎΠ»Π½ΠΈΡΠ΅Π»ΡΠ½ΡΠ΅ ΡΡΠΈΠ»ΠΈΡ ΠΏΠΎ ΡΠΎΠ²Π΅ΡΡΠ΅Π½ΡΡΠ²ΠΎΠ²Π°Π½ΠΈΡ ΠΌΠΎΠ΄Π΅Π»Π΅ΠΉ ΡΠΊΡΠΈΠ½ΠΈΠ½Π³Π° ΠΈ ΠΌΠ΅ΡΠΎΠ΄ΠΎΠ² ΠΈΡ
ΠΏΡΠΎΡΠΈΠ»Π°ΠΊΡΠΈΠΊΠΈ, ΠΏΠΎΠ²ΡΡΠ΅Π½ΠΈΡ ΠΎΠ½ΠΊΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΎΠΉ Π½Π°ΡΡΠΎΡΠΎΠΆΠ΅Π½Π½ΠΎΡΡΠΈ Π²ΡΠ°ΡΠ΅ΠΉ ΠΏΠ΅ΡΠ²ΠΈΡΠ½ΠΎΠ³ΠΎ Π·Π²Π΅Π½Π° Π·Π΄ΡΠ°Π²ΠΎΠΎΡ
ΡΠ°Π½Π΅Π½ΠΈΡ, ΠΈΠ½ΡΠΎΡΠΌΠΈΡΠΎΠ²Π°Π½Π½ΠΎΡΡΠΈ ΠΆΠ΅Π½ΡΠΊΠΎΠ³ΠΎ Π½Π°ΡΠ΅Π»Π΅Π½ΠΈΡ ΠΎ ΡΠ°ΠΊΡΠΎΡΠ°Ρ
ΡΠΈΡΠΊΠ° ΡΠ°Π·Π²ΠΈΡΠΈΡ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΠΉ ΠΌΠΎΠ»ΠΎΡΠ½ΠΎΠΉ ΠΆΠ΅Π»Π΅Π·Ρ, Π΄Π΅ΠΉΡΡΠ²ΡΡΡΠΈΡ
ΠΏΡΠΎΠ³ΡΠ°ΠΌΠΌΠ°Ρ
ΡΠΊΡΠΈΠ½ΠΈΠ½Π³Π° ΠΈ ΠΏΡΠΎΡΠΈΠ»Π°ΠΊΡΠΈΠΊΠΈ. Π‘Π²ΠΎΠ΅Π²ΡΠ΅ΠΌΠ΅Π½Π½ΠΎ Π½Π°ΡΠ°ΡΠΎΠ΅ Π»Π΅ΡΠ΅Π½ΠΈΠ΅ Π΄ΠΎΠ±ΡΠΎΠΊΠ°ΡΠ΅ΡΡΠ²Π΅Π½Π½ΡΡ
Π΄ΠΈΡΠΏΠ»Π°Π·ΠΈΠΉ ΠΌΠΎΠ»ΠΎΡΠ½ΠΎΠΉ ΠΆΠ΅Π»Π΅Π·Ρ ΡΠ²Π»ΡΠ΅ΡΡΡ Π½Π°ΠΈΠ±ΠΎΠ»Π΅Π΅ ΡΠ°Π½Π½Π΅ΠΉ ΠΈ ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΠΉ ΠΏΡΠΎΡΠΈΠ»Π°ΠΊΡΠΈΠΊΠΎΠΉ ΠΎΠ½ΠΊΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΡ
Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΠΉ
ΠΠΈΠ½Π°ΠΌΠΈΠΊΠ° ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΈΡ ΡΠΈΠΌΠΏΡΠΎΠΌΠΎΠ² ΡΠΈΠ±ΡΠΎΠ·Π½ΠΎ-ΠΊΠΈΡΡΠΎΠ·Π½ΠΎΠΉ ΠΌΠ°ΡΡΠΎΠΏΠ°ΡΠΈΠΈ Π½Π° ΡΠΎΠ½Π΅ ΡΡΠ°Π½ΡΠ΄Π΅ΡΠΌΠ°Π»Ρ-Π½ΠΎΠ³ΠΎ Π³Π΅Π»Ρ ΠΌΠΈΠΊΡΠΎΠ½ΠΈΠ·ΠΈΡΠΎΠ²Π°Π½Π½ΠΎΠ³ΠΎ ΠΏΡΠΎΠ³Π΅ΡΡΠ΅ΡΠΎΠ½Π°: ΡΠ΅Π·ΡΠ»ΡΡΠ°ΡΡ ΡΠΎΡΡΠΈΠΉΡΠΊΠΎΠ³ΠΎ ΠΌΠ½ΠΎΠ³ΠΎΡΠ΅Π½ΡΡΠΎΠ²ΠΎΠ³ΠΎ Π½Π°Π±Π»ΡΠ΄Π°ΡΠ΅Π»ΡΠ½ΠΎΠ³ΠΎ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ ΠΠ ΠΠ‘Π’
Objective. To assess the dynamics offibrocystic mastopathy symptoms regression when applying monotherapy with transdermal gel of micronized progesterone continuously for 3 and 6 months under conditions of routine clinical practice. Materials and methods. The study included 1044female patients of 34.8 Β± 0.2 years of age diagnosed with diffuse mastopathy with predominant glandular component and diffuse fibrocystic mastopathy with predominant cystic component. All the patients received therapy with transdermal gel of micronized progesterone (Progestogel product) for 3and 6 months. The data related to dynamics of the disease symptoms were evaluated: clinical examination of the lacteal gland was performed, ultrasound and mammography examinations were performed, with assessment according to Bi-RADS categories. Intensity of the pain sense modality was evaluated in dynamics using visual analog scale (VAS) of pain. Statistical analysis of the collected data was carried out using IBM SPSS 23 software. Results. In 3-6 months of the continuous use of Progestogel product, a significant reduction in the amount of the earlier revealed thickened tissue areas was observed during ultrasound examination, including the areas of 1-2 cm and those exceeding 2 cm (hyperplastic lobules, cysts). According to the analysis of the mammographic conclusions, in the course of the therapy the signs of the fat involution build-up were observed as reducing from 9.1% to 1.3%, the signs of focal fibrosis reduced from 12.9% to 5.3%; the proportion of the patients with diffuse fibrocystic mastopathy with predominant cystic component reduced by 22.4% (from 56.6% to 34.2%). Significant improvement of the disease course is as well demonstrated by the dynamics of the changes as per the assessment according to Bi-RADS categories (p < 0.05). The intensity of the pain in the mammary glands significantly reduced in the therapy dynamics; before treatment it was 62.22 Β± 0.84 scores, in 3 months 27.33 Β± 0.70 scores (p < 0.001), in 6 months 9.33 Β± 0.46scores (p < 0.001). Conclusion. The data obtained show the improvement of the life quality and reduction in the pain syndrome intensity in patients with mastalgia/mastodynia.Π¦Π΅Π»Ρ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ. ΠΡΠ΅Π½ΠΈΡΡ Π΄ΠΈΠ½Π°ΠΌΠΈΠΊΡ ΡΠ΅Π³ΡΠ΅ΡΡΠΈΠΈ ΡΠΈΠΌΠΏΡΠΎΠΌΠΎΠ² ΡΠΈΠ±ΡΠΎΠ·Π½ΠΎ-ΠΊΠΈΡΡΠΎΠ·Π½ΠΎΠΉ ΠΌΠ°ΡΡΠΎΠΏΠ°ΡΠΈΠΈ ΠΏΡΠΈ ΠΏΡΠΈΠΌΠ΅Π½Π΅Π½ΠΈΠΈ ΡΡΠ°Π½ΡΠ΄Π΅ΡΠΌΠ°Π»ΡΠ½ΠΎΠ³ΠΎ Π³Π΅Π»Ρ ΠΌΠΈΠΊΡΠΎΠ½ΠΈΠ·ΠΈΡΠΎΠ²Π°Π½Π½ΠΎΠ³ΠΎ ΠΏΡΠΎΠ³Π΅ΡΡΠ΅ΡΠΎΠ½Π° Π² Π½Π΅ΠΏΡΠ΅ΡΡΠ²Π½ΠΎΠΌ ΡΠ΅ΠΆΠΈΠΌΠ΅ Π² ΡΠ΅ΡΠ΅Π½ΠΈΠ΅ 3 ΠΈ 6ΠΌΠ΅ΡΡΡΠ΅Π².. ΠΠ°ΡΠ΅ΡΠΈΠ°Π» ΠΈ ΠΌΠ΅ΡΠΎΠ΄Ρ. Π ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠΈ ΠΏΡΠΈΠ½ΡΠ»ΠΈ ΡΡΠ°ΡΡΠΈΠ΅ 1044 ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠΊ 34,8Β±0,2Π»Π΅Ρ Ρ Π΄ΠΈΠ°Π³Π½ΠΎΠ·ΠΎΠΌ Π΄ΠΈΡΡΡΠ·Π½ΠΎΠΉ ΠΌΠ°ΡΡΠΎΠΏΠ°ΡΠΈΠΈ Ρ ΠΏΡΠ΅ΠΎΠ±Π»Π°Π΄Π°Π½ΠΈΠ΅ΠΌ ΠΆΠ΅Π»Π΅Π·ΠΈΡΡΠΎΠ³ΠΎ ΠΊΠΎΠΌΠΏΠΎΠ½Π΅Π½ΡΠ° ΠΈ Π΄ΠΈΡΡΡΠ·Π½ΠΎΠΉ ΡΠΈΠ±ΡΠΎΠ·Π½ΠΎ-ΠΊΠΈΡΡΠΎΠ·Π½ΠΎΠΉ ΠΌΠ°ΡΡΠΎΠΏΠ°ΡΠΈΠΈ Ρ ΠΏΡΠ΅ΠΎΠ±Π»Π°Π΄Π°Π½ΠΈΠ΅ΠΌ ΠΊΠΈΡΡΠΎΠ·Π½ΠΎΠ³ΠΎ ΠΊΠΎΠΌΠΏΠΎΠ½Π΅Π½ΡΠ°. ΠΡΠ΅ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΊΠΈ ΠΏΠΎΠ»ΡΡΠ°Π»ΠΈ ΡΠ΅ΡΠ°ΠΏΠΈΡ ΡΡΠ°Π½ΡΠ΄Π΅ΡΠΌΠ°Π»ΡΠ½ΡΠΌ Π³Π΅Π»Π΅ΠΌ ΠΌΠΈΠΊΡΠΎΠ½ΠΈΠ·ΠΈΡΠΎΠ²Π°Π½Π½ΠΎΠ³ΠΎ ΠΏΡΠΎΠ³Π΅ΡΡΠ΅ΡΠΎΠ½Π° (ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠΎΠΌ ΠΏΡΠΎΠΆΠ΅ΡΡΠΎΠΆΠ΅Π»Ρ) Π² ΡΠ΅ΡΠ΅Π½ΠΈΠ΅ 3-6 ΠΌΠ΅ΡΡΡΠ΅Π². ΠΡΠΏΠΎΠ»Π½ΡΠ»ΠΈ ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΈΠΉ ΠΎΡΠΌΠΎΡΡ ΠΌΠΎΠ»ΠΎΡΠ½ΠΎΠΉ ΠΆΠ΅Π»Π΅Π·Ρ, ΠΏΡΠΎΠ²ΠΎΠ΄ΠΈΠ»ΠΈ ΡΠ»ΡΡΡΠ°Π·Π²ΡΠΊΠΎΠ²ΠΎΠ΅ ΠΈ ΠΌΠ°ΠΌΠΌΠΎΠ³ΡΠ°ΡΠΈΡΠ΅ΡΠΊΠΎΠ΅ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠ΅, ΠΎΡΠ΅Π½ΠΊΡ ΠΏΠΎ ΡΠΊΠ°Π»Π΅ BI-RADS (Breast Imaging Reporting and Database System), ΠΎΡΠ΅Π½ΠΊΡ ΠΈΠ½ΡΠ΅Π½ΡΠΈΠ²Π½ΠΎΡΡΠΈ Π±ΠΎΠ»Π΅Π²ΡΡ
ΠΎΡΡΡΠ΅Π½ΠΈΠΉ Ρ ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π½ΠΈΠ΅ΠΌ Π²ΠΈΠ·ΡΠ°Π»ΡΠ½ΠΎ-Π°Π½Π°Π»ΠΎΠ³ΠΎΠ²ΠΎΠΉ ΡΠΊΠ°Π»Ρ Π±ΠΎΠ»ΠΈ. Π‘ΡΠ°ΡΠΈΡΡΠΈΡΠ΅ΡΠΊΠΈΠΉ Π°Π½Π°Π»ΠΈΠ· Π΄Π°Π½Π½ΡΡ
Π²ΡΠΏΠΎΠ»Π½ΡΠ»ΡΡ Ρ ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π½ΠΈΠ΅ΠΌ ΠΏΡΠΎΠ³ΡΠ°ΠΌΠΌΡ IBM SPSS 23. Π Π΅Π·ΡΠ»ΡΡΠ°ΡΡ. Π§Π΅ΡΠ΅Π· 3-6ΠΌΠ΅ΡΡΡΠ° Π½Π΅ΠΏΡΠ΅ΡΡΠ²Π½ΠΎΠ³ΠΎ ΠΏΡΠΈΠΌΠ΅Π½Π΅Π½ΠΈΡ ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠ° ΠΏΡΠΎΠΆΠ΅ΡΡΠΎΠΆΠ΅Π»Ρ ΠΏΡΠΈ Π£ΠΠ ΠΎΡΠΌΠ΅ΡΠ΅Π½ΠΎ Π΄ΠΎΡΡΠΎΠ²Π΅ΡΠ½ΠΎΠ΅ ΡΠΌΠ΅Π½ΡΡΠ΅Π½ΠΈΠ΅ ΡΠΈΡΠ»Π° Π²ΡΡΠ²Π»Π΅Π½Π½ΡΡ
ΡΡΠ°ΡΡΠΊΠΎΠ² ΡΠΏΠ»ΠΎΡΠ½Π΅Π½Π½ΠΎΠΉ ΡΡΡΡΠΊΡΡΡΡ, Π² ΡΠΎΠΌ ΡΠΈΡΠ»Π΅ ΡΠ°Π·ΠΌΠ΅ΡΠ°ΠΌΠΈ 1-2 ΡΠΌ ΠΈ Π±ΠΎΠ»Π΅Π΅ 2-Ρ
ΡΠΌ (Π³ΠΈΠΏΠ΅ΡΠΏΠ»Π°Π·ΠΈΡΠΎΠ²Π°Π½Π½ΡΠ΅ Π΄ΠΎΠ»ΡΠΊΠΈ, ΠΊΠΈΡΡΡ). Π‘ΠΎΠ³Π»Π°ΡΠ½ΠΎ Π°Π½Π°Π»ΠΈΠ·Ρ ΠΌΠ°ΠΌΠΌΠΎΠ³ΡΠ°ΡΠΈΡΠ΅ΡΠΊΠΈΡ
Π·Π°ΠΊΠ»ΡΡΠ΅Π½ΠΈΠΉ Π² ΡΠ΅ΡΠ΅Π½ΠΈΠ΅ ΡΠ΅ΡΠ°ΠΏΠΈΠΈ Π΄ΠΎΠ»Ρ ΠΆΠΈΡΠΎΠ²ΠΎΠΉ ΠΈΠ½Π²ΠΎΠ»ΡΡΠΈΠΈ ΠΈΠ·ΠΌΠ΅Π½ΠΈΠ»Π°ΡΡ Ρ 9,1% Π΄ΠΎ 1,3%, ΠΎΡΠ°Π³ΠΎΠ²ΠΎΠ³ΠΎ ΡΠΈΠ±ΡΠΎΠ·Π° ΡΠ½ΠΈΠΆΠ°Π»ΠΈΡΡ Ρ 12,9% Π΄ΠΎ 5,3%; Π΄ΠΎΠ»Ρ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠΊ ΠΠ€ΠΠ Ρ ΠΏΡΠ΅ΠΎΠ±Π»Π°Π΄Π°Π½ΠΈΠ΅ΠΌ ΠΊΠΈΡΡΠΎΠ·Π½ΠΎΠ³ΠΎ ΠΊΠΎΠΌΠΏΠΎΠ½Π΅Π½ΡΠ° ΡΠΎΠΊΡΠ°ΡΠΈΠ»Π°ΡΡ Π½Π° 22,4% (Ρ 56,6% Π΄ΠΎ 34,2%). ΠΠΎΡΡΠΎΠ²Π΅ΡΠ½ΠΎΠ΅ ΡΠ»ΡΡΡΠ΅Π½ΠΈΠ΅ ΡΠ΅ΡΠ΅Π½ΠΈΡ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΡ Π΄Π΅ΠΌΠΎΠ½ΡΡΡΠΈΡΡΠ΅Ρ ΡΠ°ΠΊΠΆΠ΅ Π΄ΠΈΠ½Π°ΠΌΠΈΠΊΠ° ΠΈΠ·ΠΌΠ΅Π½Π΅Π½ΠΈΠΉ ΠΏΠΎ ΡΠΊΠ°Π»Π΅ BI-RADS (p<0,05). ΠΠ½ΡΠ΅Π½ΡΠΈΠ²Π½ΠΎΡΡΡ Π±ΠΎΠ»ΠΈ Π² ΠΌΠΎΠ»ΠΎΡΠ½ΠΎΠΉ ΠΆΠ΅Π»Π΅Π·Π΅ Π΄ΠΎΡΡΠΎΠ²Π΅ΡΠ½ΠΎ ΡΠΌΠ΅Π½ΡΡΠ°Π»Π°ΡΡ Π² Π΄ΠΈΠ½Π°ΠΌΠΈΠΊΠ΅ ΡΠ΅ΡΠ°ΠΏΠΈΠΈ: Π΄ΠΎ Π»Π΅ΡΠ΅Π½ΠΈΡ 62,22Β±0,84 Π±Π°Π»Π»Π° - ΡΠ΅ΡΠ΅Π· 3 ΠΌΠ΅ΡΡΡΠ° 27,33Β±0,70 Π±Π°Π»Π»Π° (p<0,001), ΡΠ΅ΡΠ΅Π· 6ΠΌΠ΅ΡΡΡΠ΅Π² 9,33Β±0,46Π±Π°Π»Π»Π° (p<0,001). ΠΠ°ΠΊΠ»ΡΡΠ΅Π½ΠΈΠ΅. ΠΠΎΠ»ΡΡΠ΅Π½Π½ΡΠ΅ Π΄Π°Π½Π½ΡΠ΅ ΡΠ²ΠΈΠ΄Π΅ΡΠ΅Π»ΡΡΡΠ²ΡΡΡ ΠΎ ΡΠ½ΠΈΠΆΠ΅Π½ΠΈΠΈ Π²ΡΡΠ°ΠΆΠ΅Π½Π½ΠΎΡΡΠΈ Π±ΠΎΠ»Π΅Π²ΠΎΠ³ΠΎ ΡΠΈΠ½Π΄ΡΠΎΠΌΠ°, ΠΎΠ± ΡΠ»ΡΡΡΠ΅Π½ΠΈΠΈ ΠΊΠ°ΡΠ΅ΡΡΠ²Π° ΠΆΠΈΠ·Π½ΠΈ ΠΈ ΡΠ΅ΡΠ΅Π½ΠΈΡ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΡ Ρ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠΊ Ρ ΠΌΠ°ΡΡΠ°Π»Π³ΠΈΠ΅ΠΉ/ΠΌΠ°ΡΡΠΎΠ΄ΠΈΠ½ΠΈΠ΅ΠΉ
ΠΠΎΠ±ΡΠΎΠΊΠ°ΡΠ΅ΡΡΠ²Π΅Π½Π½ΡΠ΅ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΡ ΠΌΠΎΠ»ΠΎΡΠ½ΠΎΠΉ ΠΆΠ΅Π»Π΅Π·Ρ
Π ΡΡΠΊΠΎΠ²ΠΎΠ΄ΡΡΠ²Π΅ ΠΈΠ·Π»ΠΎΠΆΠ΅Π½Ρ ΡΠΎΠ²ΡΠ΅ΠΌΠ΅Π½Π½ΡΠ΅ ΠΏΡΠ΅Π΄ΡΡΠ°Π²Π»Π΅Π½ΠΈΡ ΠΎΠ± ΡΡΠΈΠΎΠ»ΠΎΠ³ΠΈΠΈ ΠΈ ΠΏΠ°ΡΠΎΠ³Π΅Π½Π΅Π·Π΅ Π΄ΠΎΠ±ΡΠΎΠΊΠ°ΡΠ΅ΡΡΠ²Π΅Π½Π½ΡΡ
Π΄ΠΈΡΠΏΠ»Π°Π·ΠΈΠΉ ΠΌΠΎΠ»ΠΎΡΠ½ΠΎΠΉ ΠΆΠ΅Π»Π΅Π·Ρ. ΠΡΠΈΠ²Π΅Π΄Π΅Π½Π° ΠΌΠΎΡΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠ°Ρ ΠΊΠ»Π°ΡΡΠΈΡΠΈΠΊΠ°ΡΠΈΡ Π΄ΠΈΡΡΡΠ·Π½ΡΡ
ΠΈ ΡΠ·Π»ΠΎΠ²ΡΡ
Π΄ΠΎΠ±ΡΠΎΠΊΠ°ΡΠ΅ΡΡΠ²Π΅Π½Π½ΡΡ
Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΠΉ ΠΌΠΎΠ»ΠΎΡΠ½ΠΎΠΉ ΠΆΠ΅Π»Π΅Π·Ρ. ΠΠΏΠΈΡΠ°Π½Π½ΡΠ΅ Π΄ΠΈΠ°Π³Π½ΠΎΡΡΠΈΡΠ΅ΡΠΊΠΈΠ΅ ΡΠ΅Ρ
Π½ΠΎΠ»ΠΎΠ³ΠΈΠΈ ΠΎΡΠ½ΠΎΠ²ΡΠ²Π°ΡΡΡΡ Π½Π° ΠΏΠΎΡΠ»Π΅Π΄Π½ΠΈΡ
Π΄ΠΎΡΡΠΈΠΆΠ΅Π½ΠΈΡΡ
ΠΌΠ΅Π΄ΠΈΡΠΈΠ½Ρ, Π½Π°ΠΊΠΎΠΏΠΈΠ²ΡΠ΅ΠΉ Π½ΠΎΠ²ΡΠ΅ ΡΠ²Π΅Π΄Π΅Π½ΠΈΡ ΠΎΠ± ΠΎΡΠΎΠ±Π΅Π½Π½ΠΎΡΡΡΡ
ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΈΡ
, ΡΠ΅Π½ΡΠ³Π΅Π½ΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΡ
, ΡΠΎΠ½ΠΎΠ³ΡΠ°ΡΠΈΡΠ΅ΡΠΊΠΈΡ
ΠΈ ΠΏΠ°ΡΠΎΠΌΠΎΡΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΡ
ΠΏΡΠΎΡΠ²Π»Π΅Π½ΠΈΠΉ ΡΡΠΎΠΉ Π³ΡΡΠΏΠΏΡ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΠΉ. Π£ΡΠΏΠ΅Ρ
ΠΈ ΠΌΠΎΠ»Π΅ΠΊΡΠ»ΡΡΠ½ΠΎΠΉ Π±ΠΈΠΎΠ»ΠΎΠ³ΠΈΠΈ ΠΏΠΎΠ·Π²ΠΎΠ»ΠΈΠ»ΠΈ ΠΎΠ±ΠΎΡΠ½ΠΎΠ²Π°ΡΡ ΠΏΠ°ΡΠΎΠ³Π΅Π½Π΅ΡΠΈΡΠ΅ΡΠΊΠΈΠ΅ ΠΌΠ΅Ρ
Π°Π½ΠΈΠ·ΠΌΡ Π²ΠΎΠ·Π΄Π΅ΠΉΡΡΠ²ΠΈΡ ΡΠ°ΠΊΡΠΎΡΠΎΠ² ΡΠΈΡΠΊΠ° Π½Π° ΡΠΎΡΠΌΠΈΡΠΎΠ²Π°Π½ΠΈΠ΅ Π΄ΠΈΡΠ³ΠΎΡΠΌΠΎΠ½Π°Π»ΡΠ½ΡΡ
ΠΏΠ΅ΡΠ΅ΡΡΡΠΎΠ΅ΠΊ ΠΌΠΎΠ»ΠΎΡΠ½ΠΎΠΉ ΠΆΠ΅Π»Π΅Π·Ρ, Π° ΡΠ°ΠΊΠΆΠ΅ Π²Π°ΡΠΈΠ°Π½ΡΡ ΠΈΡ
ΡΠ²ΠΎΠ΅Π²ΡΠ΅ΠΌΠ΅Π½Π½ΠΎΠ³ΠΎ ΠΊΠΎΠ½ΡΠ΅ΡΠ²Π°ΡΠΈΠ²Π½ΠΎΠ³ΠΎ, ΡΡΠ°ΡΠΈΠΎΠ½Π°ΡΠΎΠ·Π°ΠΌΠ΅ΡΠ°ΡΡΠ΅Π³ΠΎ ΠΈ Ρ
ΠΈΡΡΡΠ³ΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ Π»Π΅ΡΠ΅Π½ΠΈΡ, ΠΏΡΠ΅Π΄ΡΠΏΡΠ΅ΠΆΠ΄Π°ΡΡΠ΅Π³ΠΎ Π·Π»ΠΎΠΊΠ°ΡΠ΅ΡΡΠ²Π΅Π½Π½ΡΡ ΡΡΠ°Π½ΡΡΠΎΡΠΌΠ°ΡΠΈΡ. ΠΠ°Π½Ρ ΡΠ΅ΠΊΠΎΠΌΠ΅Π½Π΄Π°ΡΠΈΠΈ ΠΏΠΎ ΠΏΡΠΎΡΠΈΠ»Π°ΠΊΡΠΈΠΊΠ΅ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΠΉ, ΠΏΡΠ΅Π΄ΡΡΠ°Π²Π»Π΅Π½Π° ΠΏΡΠΎΠ³ΡΠ°ΠΌΠΌΠ° ΡΠΊΠΎΠ»Ρ ΠΆΠ΅Π½ΡΠΊΠΎΠ³ΠΎ Π·Π΄ΠΎΡΠΎΠ²ΡΡ. ΠΠ»Π»ΡΡΡΡΠ°ΡΠΈΠ²Π½ΡΠΉ ΠΌΠ°ΡΠ΅ΡΠΈΠ°Π» ΠΏΠΎΠΊΠ°Π·ΡΠ²Π°Π΅Ρ Π²ΠΎΠ·ΠΌΠΎΠΆΠ½ΠΎΡΡΠΈ ΡΠΎΠ²ΡΠ΅ΠΌΠ΅Π½Π½ΠΎΠΉ ΠΌΠ΅Π΄ΠΈΡΠΈΠ½Ρ ΠΏΡΠΈ ΠΌΠ½ΠΎΠ³ΠΎΠΎΠ±ΡΠ°Π·ΠΈΠΈ ΠΏΠ°ΡΠΎΠ»ΠΎΠ³ΠΈΠΈ ΠΌΠΎΠ»ΠΎΡΠ½ΠΎΠΉ ΠΆΠ΅Π»Π΅Π·Ρ. ΠΡΠ΅Π΄ΡΡΠ°Π²Π»Π΅Π½Π½ΡΠΉ ΠΌΠ΅ΠΆΠ΄ΠΈΡΡΠΈΠΏΠ»ΠΈΠ½Π°ΡΠ½ΡΠΉ ΠΏΠΎΠ΄Ρ
ΠΎΠ΄ ΠΊ ΠΎΡΠ²Π΅ΡΠ΅Π½ΠΈΡ ΠΏΡΠΎΠ±Π»Π΅ΠΌΡ Π΄ΠΈΡΠΏΠ»Π°Π·ΠΈΠΉ ΠΌΠΎΠ»ΠΎΡΠ½ΠΎΠΉ ΠΆΠ΅Π»Π΅Π·Ρ ΠΏΠΎΠ·Π²ΠΎΠ»ΠΈΡ ΠΏΠΎΠΏΠΎΠ»Π½ΠΈΡΡ Π±Π°Π³Π°ΠΆ Π·Π½Π°Π½ΠΈΠΉ Π²ΡΠ°ΡΠ΅ΠΉ Π½Π΅ ΡΠΎΠ»ΡΠΊΠΎ Π² ΡΠ²ΠΎΠ΅ΠΉ ΡΠ·ΠΊΠΎΠΉ ΡΠΏΠ΅ΡΠΈΠ°Π»ΡΠ½ΠΎΡΡΠΈ, Π½ΠΎ ΠΈ Π² ΡΠΌΠ΅ΠΆΠ½ΡΡ
Π΄ΠΈΡΡΠΈΠΏΠ»ΠΈΠ½Π°Ρ
Π΄Π»Ρ ΠΏΡΠ°Π²ΠΈΠ»ΡΠ½ΠΎΠ³ΠΎ Π²ΡΠ±ΠΎΡΠ° Π΄ΠΈΠ°Π³Π½ΠΎΡΡΠΈΡΠ΅ΡΠΊΠΎΠΉ ΡΠ°ΠΊΡΠΈΠΊΠΈ, Π°Π΄Π΅ΠΊΠ²Π°ΡΠ½ΠΎΠ³ΠΎ ΠΌΠ΅ΡΠΎΠ΄Π° Π»Π΅ΡΠ΅Π½ΠΈΡ ΠΈ ΠΏΡΠΎΡΠΈΠ»Π°ΠΊΡΠΈΠΊΠΈ ΡΠ°ΠΊΠ°. ΠΡΠ΅Π΄Π½Π°Π·Π½Π°ΡΠ΅Π½ΠΎ Π΄Π»Ρ Π²ΡΠ°ΡΠ΅ΠΉ ΠΎΠ±ΡΠ΅ΠΉ ΠΏΡΠ°ΠΊΡΠΈΠΊΠΈ, Ρ
ΠΈΡΡΡΠ³ΠΎΠ², ΡΠ΅Π½ΡΠ³Π΅Π½ΠΎΠ»ΠΎΠ³ΠΎΠ², ΡΠΏΠ΅ΡΠΈΠ°Π»ΠΈΡΡΠΎΠ² ΡΠ»ΡΡΡΠ°Π·Π²ΡΠΊΠΎΠ²ΠΎΠΉ Π΄ΠΈΠ°Π³Π½ΠΎΡΡΠΈΠΊΠΈ, Π°ΠΊΡΡΠ΅ΡΠΎΠ²-Π³ΠΈΠ½Π΅ΠΊΠΎΠ»ΠΎΠ³ΠΎΠ², ΠΎΠ½ΠΊΠΎΠ»ΠΎΠ³ΠΎΠ² ΠΈ Π΄ΡΡΠ³ΠΈΡ
ΡΠΏΠ΅ΡΠΈΠ°Π»ΠΈΡΡΠΎΠ², Π·Π°Π½ΠΈΠΌΠ°ΡΡΠΈΡ
ΡΡ ΠΏΠ°ΡΠΎΠ»ΠΎΠ³ΠΈΠ΅ΠΉ ΠΌΠΎΠ»ΠΎΡΠ½ΡΡ
ΠΆΠ΅Π»Π΅Π·
Π€ΠΠΠ―Π ΠΠΠ ΠΠΠΠΠ§ΠΠΠ ΠΠΠΠΠΠ«. ΠΠΠΠΠΠΠΠ‘ΠΠΠ― ΠΠ£Π§ΠΠΠΠ― ΠΠΠΠΠΠΠ‘Π’ΠΠΠ Π ΠΠΠ§ΠΠΠΠ
F ilariasis is a tropical disease caused by the parasite Dirofilaria repens. The lesion of the breast occurs in 10%. Purpose. To present a clinical case of a woman with breast pathology. Materials and methods. The condition did not manifest clinically. Detection of atypical cyst in the breast using ultrasound technology and its subsequent biopsy allowed to confirm the pathology. Results. The possibilities of an integrated approach in the diagnosis of breast lesions and minimally invasive treatment of a patient with a parasitic lesion of the breast are demonstrated.Π€ ΠΈΠ»ΡΡΠΈΠΎΠ· - ΡΡΠΎ ΡΡΠΎΠΏΠΈΡΠ΅ΡΠΊΠΎΠ΅ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΠ΅, Π²ΡΠ·Π²Π°Π½Π½ΠΎΠ΅ ΠΏΠ°ΡΠ°Π·ΠΈΡΠΎΠΌ Dirofilaria repens. ΠΠΎΡΠ°ΠΆΠ΅Π½ΠΈΠ΅ ΠΌΠΎΠ»ΠΎΡΠ½ΠΎΠΉ ΠΆΠ΅Π»Π΅Π·Ρ Π²ΡΡΡΠ΅ΡΠ°Π΅ΡΡΡ Π² 10%. Π¦Π΅Π»Ρ. ΠΡΠ΅Π΄ΡΡΠ°Π²ΠΈΡΡ ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΎΠ΅ Π½Π°Π±Π»ΡΠ΄Π΅Π½ΠΈΠ΅ ΠΆΠ΅Π½ΡΠΈΠ½Ρ Ρ ΠΏΠ°ΡΠΎΠ»ΠΎΠ³ΠΈΠ΅ΠΉ ΠΌΠΎΠ»ΠΎΡΠ½ΠΎΠΉ ΠΆΠ΅Π»Π΅Π·Ρ. ΠΠ°ΡΠ΅ΡΠΈΠ°Π»Ρ ΠΈ ΠΌΠ΅ΡΠΎΠ΄Ρ. Π‘ΠΎΡΡΠΎΡΠ½ΠΈΠ΅ ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΈ Π½Π΅ ΠΏΡΠΎΡΠ²Π»ΡΠ»ΠΎΡΡ. ΠΡΡΠ²Π»Π΅Π½ΠΈΠ΅ Π°ΡΠΈΠΏΠΈΡΠ½ΠΎΠΉ ΠΊΠΈΡΡΡ Π² ΠΌΠΎΠ»ΠΎΡΠ½ΠΎΠΉ ΠΆΠ΅Π»Π΅Π·Π΅ Ρ ΠΏΡΠΈΠΌΠ΅Π½Π΅Π½ΠΈΠ΅ΠΌ ΡΠ»ΡΡΡΠ°Π·Π²ΡΠΊΠΎΠ²ΡΡ
ΡΠ΅Ρ
Π½ΠΎΠ»ΠΎΠ³ΠΈΠΉ ΠΈ ΠΏΠΎΡΠ»Π΅Π΄ΡΡΡΠ°Ρ Π΅Π΅ Π±ΠΈΠΎΠΏΡΠΈΡ ΠΏΠΎΠ·Π²ΠΎΠ»ΠΈΠ»ΠΈ ΠΏΠΎΠ΄ΡΠ²Π΅ΡΠ΄ΠΈΡΡ ΠΏΠ°ΡΠΎΠ»ΠΎΠ³ΠΈΡ. Π Π΅Π·ΡΠ»ΡΡΠ°ΡΡ. ΠΡΠΎΠ΄Π΅ΠΌΠΎΠ½ΡΡΡΠΈΡΠΎΠ²Π°Π½Ρ Π²ΠΎΠ·ΠΌΠΎΠΆΠ½ΠΎΡΡΠΈ ΠΊΠΎΠΌΠΏΠ»Π΅ΠΊΡΠ½ΠΎΠ³ΠΎ ΠΏΠΎΠ΄Ρ
ΠΎΠ΄Π° Π² Π΄ΠΈΠ°Π³Π½ΠΎΡΡΠΈΠΊΠ΅ ΠΏΠΎΡΠ°ΠΆΠ΅Π½ΠΈΠΉ ΠΌΠΎΠ»ΠΎΡΠ½ΠΎΠΉ ΠΆΠ΅Π»Π΅Π·Ρ ΠΈ ΠΌΠ°Π»ΠΎΠΈΠ½Π²Π°Π·ΠΈΠ²Π½ΠΎΠ³ΠΎ Π»Π΅ΡΠ΅Π½ΠΈΡ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΊΠΈ Ρ ΠΏΠ°ΡΠ°Π·ΠΈΡΠ°ΡΠ½ΡΠΌ ΠΏΠΎΡΠ°ΠΆΠ΅Π½ΠΈΠ΅ΠΌ ΠΌΠΎΠ»ΠΎΡΠ½ΠΎΠΉ ΠΆΠ΅Π»Π΅Π·Ρ
Use of mastodynon for the treatment of mastalgia in patients after augmentation mammoplasty
Objective. To investigate the effectiveness of Mastodynon in women with benign breast diseases, which are accompanied by mastalgia after endoprosthetics of mammary glands for cosmetic purposes. Subjects and methods. The effectiveness of therapy with the herbal preparation Mastodynon was evaluated in 42 women with symptoms of mastalgia after augmentation mammoplasty. The patients used the drug as cycles of 1 tablet twice daily over a 3-month period at a 2.5β3 month interval. To analyze the results, the patients were divided into 3 groups. The study was conducted for 1 year through comprehensive survey with a questionnaire every 6 months. Results. After 6 months of Mastodynon intake, the questionnaire survey of patients showed varying degrees of positive results in 64.2% of cases. Following 1 year, the survey revealed a stable positive effect in 80.9% of cases. Conclusion. Mastodynon showed a high effectiveness and a good tolerance in treating mastalgia in women after endoprosthetics of mammary glands for cosmetic purposes. The administration of Mastodynon improved quality of life in patients. Β© Bionika Media Ltd
Breast filariasis. Complex diagnostic and treatment [Π€ΠΠΠ―Π ΠΠΠ ΠΠΠΠΠ§ΠΠΠ ΠΠΠΠΠΠ«. ΠΠΠΠΠΠΠΠ‘ΠΠΠ― ΠΠ£Π§ΠΠΠΠ― ΠΠΠΠΠΠΠ‘Π’ΠΠΠ Π ΠΠΠ§ΠΠΠΠ]
Filariasis is a tropical disease caused by the parasite Dirofilaria repens. The lesion of the breast occurs in 10%. Purpose. To present a clinical case of a woman with breast pathology. Materials and methods. The condition did not manifest clinically. Detection of atypical cyst in the breast using ultrasound technology and its subsequent biopsy allowed to confirm the pathology. Results. The possibilities of an integrated approach in the diagnosis of breast lesions and minimally invasive treatment of a patient with a parasitic lesion of the breast are demonstrated. Β© 2019 Russian Electronic Journal of Radiology. All rights reserved
Mammaglobin in peripheral blood & tumor in breast cancer patients
Currently, no molecular biological markers do exist for early diagnosis of breast cancer. One of the possible candidates for the marker of early breast cancer is mammaglobin (MGB1) or SCGB2A2 (secretoglobin, family 2A, member 2), characterized by the maximal expression level in early breast cancer. Using the RT-PCR method MGB1 mRNA expression was examined in 57 tumor tissue samples and 57 samples of morphologically non-malignant tissue (MNT) of breast cancer (BC) patients. Specificity and sensitivity of the MGB1 mRNA assay in peripheral blood of BC patients was evaluated by nested PCR. 169 blood samples (from 95 BC patients, 22 from patients with benign breast tumors, 28 from patients with tumors of other localizations, and 24 samples from healthy donors) have been analyzed. MGB1 expression was significantly higher in BC tissue samples compared to MNT (p=0.0019). The maximal expression level was in the samples T1 (p=0.013), stage I BC (p=0.037), GI (p=0.0019). The MGB1 expression positively correlated with expression of estrogen (p = 0,034) and progesterone (p=0.0004) receptors. Sensitivity and specificity of the MGB1 mRNA assay in peripheral blood were 60.6% and 92.3%, respectively. Expression of MGB1 was higher in BC than MNT and it decreased during BC progression. The sensitivity and specificity of the MGB1 mRNA assay may be used as an additional diagnostic method